News
ENTO
0.9744
-10.61%
-0.1156
Weekly Report: what happened at ENTO last week (0708-0712)?
Weekly Report · 11h ago
ENTERO THERAPEUTICS ANNOUNCES EXERCISE OF WARRANTS AND ISSUANCE OF NEW WARRANTS IN A PRIVATE PLACEMENT FOR $1.9 MILLION GROSS PROCEEDS
Reuters · 4d ago
Weekly Report: what happened at ENTO last week (0701-0705)?
Weekly Report · 07/08 09:32
Weekly Report: what happened at ENTO last week (0624-0628)?
Weekly Report · 07/01 09:32
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Assure stock is rocketing more than 128% after withdrawing a proposed public offering. Vigil Neuroscience shares are soaring over 40% on a $40 million investment. Public offering updates, new investments an earnings report and more are the biggest pre-market stock movers today.
Investorplace · 06/27 11:34
Entero Therapeutics Publishes Innovative Celiac Disease Research in Top Gastroenterology Journal
Entero Therapeutics, Inc. Is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. The company has published a new scale for celiac disease. The new scale includes both Morphology and Inflammation.
Benzinga · 06/27 10:04
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
Barchart · 06/27 05:00
Weekly Report: what happened at ENTO last week (0617-0621)?
Weekly Report · 06/24 09:34
Entero Therapeutics Executive Team Strategic Reshuffle
TipRanks · 06/20 21:04
Weekly Report: what happened at ENTO last week (0610-0614)?
Weekly Report · 06/17 09:32
12 Health Care Stocks Moving In Wednesday's After-Market Session
Holdco Nuvo Group DG (NASDAQ:NUVO) shares increased by 21.5% to $1.92 during Wednesday's after-market session. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 5.92%. Entero Therapeutics (NASdaq:ENTO) shares rose by 8.69%.
Benzinga · 06/12 20:31
12 Health Care Stocks Moving In Monday's After-Market Session
Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. LifeMD stock rose 5.81% in the same period. Losers Vicarious Surgical (NYSE:RBOT) and ProKidney stock fell 15.6% during the session.
Benzinga · 06/10 20:31
12 Health Care Stocks Moving In Monday's Pre-Market Session
Calidi Biotherapeutics shares rose 29.7% to $0.25 during Monday's pre-market session. Entero Therapeutics (NASDAQ:ENTO) shares rose 22.41% during the session. Co-Diagnostics stock moved upwards by 14.07%. Sunshine Biopharma and Skye Bioscience were among the losers.
Benzinga · 06/10 12:06
Weekly Report: what happened at ENTO last week (0603-0607)?
Weekly Report · 06/10 09:32
Weekly Report: what happened at ENTO last week (0527-0531)?
Weekly Report · 06/03 09:33
Weekly Report: what happened at ENTO last week (0520-0524)?
Weekly Report · 05/27 09:34
Weekly Report: what happened at ENTO last week (0513-0517)?
Weekly Report · 05/20 09:33
First Wave Bio Announces New Ticker Symbol and Corporate Identity
TipRanks · 05/16 11:32
First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease
Entero Therapeutics, Inc. Unveiled its new corporate name and website. The company is focused on the development of targeted therapies for gastrointestinal diseases. Entero's common stock will commence trading on May 17, 2024, on the Nasdaq Capital Market. The rebranding reflects the Company's focus on addressing celiac disease.
Benzinga · 05/16 11:30
More
Webull provides a variety of real-time ENTO stock news. You can receive the latest news about First Wave Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENTO
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.